Premium
THE EFFECT OF lα‐HYDROXYVITAMIN D 3 IN PRE‐DIALYSIS RENAL BONE DISEASE
Author(s) -
PIERIDES A. M.,
ELLIS H. A.,
SIMPSON W.,
COOK D.,
KERR D. N. S.
Publication year - 1977
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1977.tb03370.x
Subject(s) - osteomalacia , medicine , renal osteodystrophy , parathyroidectomy , vitamin d and neurology , endocrinology , secondary hyperparathyroidism , rickets , osteitis fibrosa cystica , bone disease , hyperparathyroidism , chronic kidney disease mineral and bone disorder , osteodystrophy , dialysis , kidney disease , parathyroid hormone , osteoporosis , calcium
SUMMARY Assessment of 18 azotaemic patients treated with long‐term 1 a‐hydroxyvitamin D, (lα‐OHD 3 ) confirms the generally favourable effect of this analogue of 1,25‐dihydroxyvitamin D 3 in azotaemic osteodystrophy. Growing chddren with radiological rickets respond very well as do adults showing mild hyperpara‐thyroidism with or without osteomalacia. However, patients with severe‘pure’hyperparathyroidism and features of autonomy do not respond well and in such patients lα‐OHD 3 alone should be avoided. Phosphate restriction and occasionally a sub‐total parathyroidectomy may be indicated in these patients.